Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects

被引:125
作者
Smolenski, A [1 ]
Burkhardt, AM [1 ]
Eigenthaler, M [1 ]
Butt, E [1 ]
Gambaryan, S [1 ]
Lohmann, SM [1 ]
Walter, U [1 ]
机构
[1] Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany
关键词
protein kinase inhibitors; cGMP analogs; KT5823; VASP; atrial natriuretic peptides;
D O I
10.1007/PL00005234
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NO and cGMP have emerged as important signal transduction mediators of the effects of certain hormones, inter-/intracellular signals, toxins and drugs. However, a major challenge is to define relevant criteria for determining which of the many NO and/or cGMP effects are dependent on cGMP-dependent protein kinases (cGKs). Important criteria include that: (1) the cell types/tissues investigated contain at least one form of cGK which is activated by the cGMP-elevating agent in the intact cell system; (2) specific activators/inhibitors of cGKs mimic/block the effects of cGMP-elevating agents in the intact cell system; and (3) the cGMP effect is absent or blunted in cGK-deficient systems, or can be reconstituted by the introduction of active cGKs. Previously, analysis of cGK activity in intact cells has been very difficult. However, the analysis of vasodilator-stimulated phosphoprotein (VASP) phosphorylation by polyclonal antibodies and newly developed monoclonal antibodies, each of which specifically recognize different phosphorylation sites, allows the quantitative measurement of cGK activity in intact cells. With the use of these methods, the properties of certain cGK mutants, cGK activators (cGMP, 8-Br-cGMP, 8-pCPT-cGMP) as well as various "specific cGK inhibitors" (KT 5823, Rp-8Br-PET-cGMPS, Rp-8-pCPT-cGMPS, H8 and H89) were investigated. Although these "specific cGK inhibitors" have been widely used to establish or rule out functional roles of cGKs, very few studies have actually addressed the efficiency/specificity of such compounds in intact cells. Our results demon strate that these inhibitors are useful tools only when used in combination with other experimental approaches and biochemical evidence.
引用
收藏
页码:134 / 139
页数:6
相关论文
共 40 条
[1]  
BELTMAN J, 1995, MOL PHARMACOL, V47, P330
[2]   ANALYSIS OF THE FUNCTIONAL-ROLE OF CGMP-DEPENDENT PROTEIN-KINASE IN INTACT HUMAN PLATELETS USING A SPECIFIC ACTIVATOR 8-PARA-CHLOROPHENYLTHIO-CGMP [J].
BUTT, E ;
NOLTE, C ;
SCHULZ, S ;
BELTMAN, J ;
BEAVO, JA ;
JASTORFF, B ;
WALTER, U .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (12) :2591-2600
[3]   Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS [J].
Butt, E ;
Pohler, D ;
Genieser, HG ;
Huggins, JP ;
Bucher, B .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) :3110-3116
[4]   (RP)-8-PCPT-CGMPS, A NOVEL CGMP-DEPENDENT PROTEIN-KINASE INHIBITOR [J].
BUTT, E ;
EIGENTHALER, M ;
GENIESER, HG .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 269 (02) :265-268
[5]   INHIBITION OF CGMP-DEPENDENT PROTEIN-KINASE BY (RP)-GUANOSINE 3',5'-MONOPHOSPHOROTHIOATES [J].
BUTT, E ;
VANBEMMELEN, M ;
FISCHER, L ;
WALTER, U ;
JASTORFF, B .
FEBS LETTERS, 1990, 263 (01) :47-50
[6]   THE CGMP-DEPENDENT PROTEIN-KINASE - GENE, PROTEIN, AND FUNCTION [J].
BUTT, E ;
GEIGER, J ;
JARCHAU, T ;
LOHMANN, SM ;
WALTER, U .
NEUROCHEMICAL RESEARCH, 1993, 18 (01) :27-42
[7]  
BUTT E, 1994, J BIOL CHEM, V269, P14509
[8]  
BUTT E, 1996, PRACT APPROACH SER, P259
[10]  
EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526